RTP Mobile Logo
Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Advanced Prostate Cancer
Released June 2017

Proceedings from a CME symposium held at the 2017 Genitourinary Cancers Symposium. Featuring perspectives from Drs Celestia S Higano, William K Oh, Daniel P Petrylak, A Oliver Sartor and Howard I Scher. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer (PC).

    OVERVIEW OF ACTIVITY
    Cancers of the genitourinary (GU) system affect hundreds of thousands of individuals within the United States each year and account for almost 30% of new cancer diagnoses. Although GU cancers are a diverse array of distinct diseases, tumors of the prostate are among the most prevalent and are therefore the topic of extensive ongoing clinical research. Consequently, the clinical management of PC is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets of relevance to the continuous delivery of quality cross-functional care.

    These proceedings from a CME symposium during the Genitourinary Cancers Symposium explore the most significant therapeutic advances during the previous year by using the perspectives of leading GU cancer experts on challenging cases and questions submitted by clinicians in the community to frame a relevant discussion of how this information has aided in the refinement of current routine clinical practice and ongoing research. This CME activity will help medical and radiation oncologists, urologists and other allied healthcare professionals find answers to the individualized questions and concerns that they frequently encounter and in turn provide high-quality cancer care.

    LEARNING OBJECTIVES

    • Appraise recent data on diagnostic and therapeutic advances in advanced PC, and integrate this information, as appropriate, into current clinical care.
    • Recall existing and emerging research information demonstrating the effects of secondary hormonal interventions on quality and quantity of life for patients with castration-resistant PC (CRPC), and use this information to guide therapeutic decision-making.
    • Explore emerging data on the use of cytotoxic therapy in the setting of hormone-sensitive advanced PC, and consider this information when designing initial treatment plans for appropriate individuals.
    • Effectively apply evidence-based research findings in the determination of best-practice sequencing of available immunotherapeutic, chemotherapeutic and secondary hormonal agents for patients with metastatic CRPC.
    • Consider available research data and expert perspectives on the efficacy and safety of radium-223 chloride as monotherapy or in combination with other treatment modalities for advanced PC, and use this information to appropriately integrate this radiopharmaceutical agent into clinical practice.
    • Explore the emerging data and active research evaluating novel strategies in the setting of PSA-only recurrent or advanced PC, and discuss the biologic basis for the clinical activity of individual therapies under investigation.
    • Counsel appropriately selected patients with PC about the availability of and participation in ongoing clinical trials.

    ACCREDITATION STATEMENT
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Research To Practice. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Penn State College of Medicine designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GUCancers17/CME.

    CONTENT VALIDATION AND DISCLOSURES
    It is the policy of Research To Practice and Penn State College of Medicine to ensure balance, independence, objectivity and scientific rigor in all their educational programs. All faculty, planners and managers participating in this activity are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest. Research To Practice and Penn State College of Medicine ensured that any conflicts of interest were resolved before the educational activity occurred.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Celestia S Higano, MD
    Professor of Medicine and Urology
    University of Washington School of Medicine
    Member, Fred Hutchinson Cancer Research Center
    Seattle Cancer Care Alliance
    Seattle, Washington

    Advisory Committee: Asana BioSciences, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Churchill Pharmaceuticals LLC, Clovis Oncology, Dendreon Pharmaceuticals Inc, Ferring Pharmaceuticals, PAREXEL International Corporation; Contracted Research: Algeta/Bayer HealthCare Pharmaceuticals, Aptevo Therapeutics, Aragon Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Genentech BioOncology, Medivation Inc, a Pfizer Company, Pfizer Inc, Takeda Oncology; Leadership Position (spouse): Cell Therapeutics Inc.

    William K Oh, MD
    Chief, Division of Hematology and Medical Oncology
    Professor of Medicine and Urology
    Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
    Icahn School of Medicine at Mount Sinai
    Associate Director of Clinical Research
    The Tisch Cancer Institute
    Mount Sinai Health System
    New York, New York

    Consulting Agreements: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Churchill Pharmaceuticals LLC, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Sanofi Genzyme, Tokai Pharmaceuticals Inc.

    Daniel P Petrylak, MD
    Professor of Medicine
    Director, Prostate and GU Medical Oncology
    Co-Director, Signal Transduction Program
    Yale Cancer Center
    New Haven, Connecticut

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Pharmaceuticals Inc, Exelixis Inc, Ferring Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Medivation Inc, a Pfizer Company, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology, Tyme; Contracted Research: Celgene Corporation, Dendreon Pharmaceuticals Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Johnson & Johnson Pharmaceuticals, OncoGenex Pharmaceuticals Inc, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Takeda Oncology; Stock Ownership: Bellicum Pharmaceuticals Inc, Tyme.

    A Oliver Sartor, MD
    Medical Director, Tulane Cancer Center
    Laborde Professor of Cancer Research
    Professor of Medicine and Urology
    Tulane Medical School
    New Orleans, Louisiana

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Johnson & Johnson Pharmaceuticals, Medivation Inc, a Pfizer Company, OncoGenex Pharmaceuticals Inc, Sanofi Genzyme, Tokai Pharmaceuticals Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Endocyte Inc, Innocrin Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Sanofi Genzyme.

    Howard I Scher, MD
    Chief, Genitourinary Oncology Service
    D Wayne Calloway Chair in Urologic Oncology
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee and Consulting Agreements: Clovis Oncology, Ferring Pharmaceuticals, Janssen Biotech Inc, Merck, Sanofi Genzyme, WCG Oncology; Board of Directors: Asterias Biotherapeutics; Contracted Research: Illumina Inc, Innocrin Pharmaceuticals, Janssen Biotech Inc, Medivation Inc, a Pfizer Company.

    CONSULTING MEDICAL ONCOLOGISTS — The following consulting medical oncologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Philip L Brooks, MD
    Hematologist-Medical Oncologist
    CancerCare of Maine/Eastern Maine Medical Center
    Brewer, Maine

    No relevant conflicts of interest to disclose.

    Raoul S Concepcion, MD
    Director
    The Advanced Therapeutic Center of Urology Associates 
    Nashville, Tennessee

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genomic Health Inc, Integra Connect LLC; Speakers Bureau: Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Sanofi Genzyme.

    Jewel Johl, MD
    Diablo Valley Oncology
    Pleasant Hill, California

    Speakers Bureau: Takeda Oncology.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz PharmaceuticalsInc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    PENN STATE COLLEGE OF MEDICINE — Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and Penn State College of Medicine do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas Pharma Global Development Inc/Medivation Inc, a Pfizer Company, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Janssen Biotech Inc and Sanofi Genzyme.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: June 5, 2017
    Expiration date: June 5, 2018

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
 
  • Intro — Optimal Integration of Chemotherapy into the Management of Metastatic Prostate Cancer
    Dr Oh
  • Presentation — Optimal Integration of Chemotherapy into the Management of Metastatic Prostate Cancer
    Dr Oh
  • Intro — Sequence and Selection of Secondary Hormonal Therapy, Immunotherapy and Cytotoxic Therapy for Patients with Metastatic Prostate Cancer
    Dr Higano
  • Presentation — Sequence and Selection of Secondary Hormonal Therapy, Immunotherapy and Cytotoxic Therapy for Patients with Metastatic Prostate Cancer
    Dr Higano
  • Closing — Sequence and Selection of Secondary Hormonal Therapy, Immunotherapy and Cytotoxic Therapy for Patients with Metastatic Prostate Cancer
    Dr Higano
  • Intro — Bone-Targeted Therapy for Patients with Metastatic Disease
    Dr Sartor
  • Presentation — Bone-Targeted Therapy for Patients with Metastatic Disease
    Dr Sartor
  • Intro — Protocol and Nonresearch Management of PSA-Only Relapse
    Dr Scher
  • Presentation — Protocol and Nonresearch Management of PSA-Only Relapse
    Dr Scher
  • Intro — Other Promising Novel Agents and Strategies Under Investigation
    Dr Petrylak
  • Presentation — Other Promising Novel Agents and Strategies Under Investigation
    Dr Petrylak